Therapeutic Potential of Sotagliflozin in Animal Models of Non-alcoholic Fatty Liver Disease with and without Diabetes

Abstract

Purpose

Sotagliflozin, a dual SGLT1/2 inhibitor, enhances glucagon like peptide-1 (GLP-1) levels and GLP-1 receptor agonists are used to manage non-alcoholic fatty liver disease (NAFLD). Study investigates the effects of sotagliflozin on NAFLD, alone and combined with linagliptin, comparing outcomes in normoglycemic and hyperglycemic animal models.

Methods

Obese fatty liver disease (FLD) model was induced by high-fat diet (HFD) feeding, while a diabetic non-alcoholic steatohepatitis (NASH) model was developed by administering a single dose of streptozotocin to neonatal mice, followed by HFD feeding post-weaning. At termination of the study, parameters including biochemical markers, inflammatory cytokines, hepatic lipid content, and histopathology were assessed.

Results

In NASH mice, sotagliflozin and linagliptin reduced hepatic triglycerides by 60% and 44%, respectively, and cholesterol by 46% and 49%. Their combination further decreased triglycerides by 68.5% and cholesterol by 83.9%. In FLD mice, sotagliflozin and linagliptin reduced triglycerides by 33% and 17%, respectively, and cholesterol by 46% and 21%. Combination treatment offered no benefit, reducing triglycerides by 38% and cholesterol by 27%. Both the treatments improved plasma fibroblast growth factor 21, hepatic interlukin-6, glucose tolerance, steatosis and mitigated fat pad weight, but their combination did not show additional benefit. However, combination treatment demonstrated added benefit in modulating NAFLD activity score, liver enzymes, glycogenated hepatic nuclei, plasma glucose and active GLP-1 levels.

Conclusion

Study underscores sotagliflozinʼs potential to mitigate NAFLD and highlights the benefit of combining it with linagliptin in hyperglycemic NASH model, which showed limited efficacy in normoglycemic FLD mice.

Keywords

antidiabetic drugs - endocrine pharmacology - metabolic disorders - lipidlowering drugs - insulin/glucagons

Publication History

Received: 12 January 2025

Accepted: 10 March 2025

Article published online:
14 April 2025

• References

• 1 Jahn D, Rau M, Wohlfahrt J. et al. Non-Alcoholic steatohepatitis: from pathophysiology to novel therapies. Dig Dis 2016; 34: 356-363
• 2 Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver International 2017; 37: 81-84
• 3 Duarte SMB, Stefano JT, Vanni DS. et al. Impact of current diet at the risk of non-alcoholic fatty liver disease (NAFLD). Arq Gastroenterol 2019; 56: 431-439
• 4 Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013; 48: 434-441
• 5 Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for non-alcoholic fatty liver disease: Emerging targets and drug candidates. Biomedicines. 2022; 26: 274
• 6 Luo Q, Wei R, Cai Y. et al. Efficacy of off-label therapy for non-alcoholic fatty liver disease in improving non-invasive and invasive biomarkers: A systematic review and network meta-analysis of randomized controlled trials. Front Med (Lausanne) 2022; 9: 793203
• 7 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 2017; 37: 97-103
• 8 Kuchay MS, Krishan S, Mishra SK. et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 2020; 63: 2434-2445
• 9 Klein T, Fujii M, Sandel J. et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol 2014; 47: 137-149
• 10 Bae JC. DPP-4 inhibitor in type 2 diabetes mellitus patient with non-alcoholic fatty liver disease: achieving two goals at once?. Endocrinol Metab (Seoul) 2022; 37: 858-860
• 11 Aso Y, Kato K, Sakurai S. et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract 2019; 73: e13335
• 12 Phrueksotsai S, Pinyopornpanish K, Euathrongchit J. et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021; 36: 2952-2959
• 13 Shimizu M, Suzuki K, Kato K. et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019; 21: 285-292
• 14 Nasiri-Ansari N, Nikolopoulou C, Papoutsi K. et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-/-) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci 2021; 22: 818
• 15 Meng Z, Liu X, Li T. et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol 2021; 94: 107492
• 16 Li L, Li Q, Huang W. et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol 2021; 12: 589273
• 17 Hazem RM, Ibrahim AZ, Ali DA. et al. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int Immunopharmacol 2022; 104: 108503
• 18 Ma Y, Zhang G, Kuang Z. et al. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related non-alcoholic fatty liver disease. Front Pharmacol 2022; 13: 944886
• 19 Petito-da-Silva TI, Souza-Mello V, Barbosa-da-Silva S. Empagliflozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol Cell Endocrinol 2019; 498: 110539
• 20 Qiao P, Jia Y, Ma A. et al. Dapagliflozin protects against non-alcoholic steatohepatitis in db/db mice. Front Pharmacol 2022; 19: 934136
• 21 Kahl S, Gancheva S, Straßburger K. et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 2020; 2: 298-305
• 22 Taheri H, Malek M, Ismail-Beigi F. et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A randomized, double-blind, placebo-controlled trial. Adv Ther 2020; 11: 4697-4708
• 23 Lai LL, Vethakkan SR, Nik Mustapha NR. et al. Empagliflozin for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 2020; 65: 623-631
• 24 Novel Drugs. approval for 2023 https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 Accessed on 10 August 2023
• 25 Zambrowicz B, Ding ZM, Ogbaa I. et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013; 35: 273-285.e7
• 26 Powell DR, Smith M, Greer J. et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp 2013; 345: 250-259
• 27 David-Silva A, Esteves JV, Morais MRPT. et al. Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice. Diabetes Metab Syndr Obes 2020; 13: 739-751
• 28 Jojima T, Tomotsune T, Iijima T. et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016; 8: 1-11
• 29 Zhong F, Zhou X, Xu J. et al. Rodent models of non-alcoholic fatty liver disease. Digestion. 2020; 101: 522-535
• 30 Edvardsson U, Ljungberg A, Lindén D. et al. PPARα activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res 2006; 47: 329-340
• 31 Kleiner DE, Brunt EM, Van Natta M. et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321
• 32 Jahn D, Kircher S, Hermanns HM. et al. Animal models of NAFLD from a hepatologistʼs point of view. Biochim Biophys Acta Mol Basis Dis 2019; 1865: 943-953
• 33 Tahara A, Kurosaki E, Yokono M. et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013; 715: 246-255
• 34 Xu L, Nagata N, Nagashimada M. et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. E Bio Medicine 2017; 20: 137-149
• 35 Xu L, Nagata N, Chen G. et al. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res Care 2019; 25: e000783
• 36 Perakakis N, Chrysafi P, Feigh M. et al. Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH. Int J Mol Sci 2021; 22: 6332
• 37 Devenny JJ, Godonis HE, Harvey SJ. et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012; 20: 1645-1652
• 38 Zhuge F, Ni Y, Nagashimada M. et al. DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes 2016; 65: 2966-2979
• 39 Hansen HH, Grønlund RV, Baader-Pagler T. et al. Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice. Sci Rep 2021; 11: 8060
• 40 Klein S, Gastaldelli A, Yki-Järvinen H. et al. Why does obesity cause diabetes?. Cell Metab 2022; 34: 11-20
• 41 Nakano S, Katsuno K, Isaji M. et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol 2015; 5: 190-198
• 42 Chavez AO, Molina-Carrion M, Abdul-Ghani MA. et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32: 1542-1546
• 43 Barb D, Bril F, Kalavalapalli S. et al. Plasma fibroblast growth factor 21 is associated with severity of non-alcoholic steatohepatitis in patients with obesity and type 2 diabetes. J Clin Endocrinol Metab 2019; 104: 3327-3336
• 44 Fisher FM, Chui PC, Antonellis PJ. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789
• 45 Eriksson JW, Lundkvist P, Jansson PA. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018; 61: 1923-1934
• 46 Samson SL, Sathyanarayana P, Jogi M. et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093-30100
• 47 Giannini C, Feldstein AE, Santoro N. et al. Circulating levels of FGF-21 in obese youth: Associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab 2013; 98: 2993-3000
• 48 Jiang S, Yan C, Fang QC. et al. Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem 2014; 43: 29751-29765
• 49 Casagrande BP, de Souza DV, Ribeiro DA. et al. Hepatic inflammation precedes steatosis and is mediated by visceral fat accumulation. J Endocrinol 2020; 3: 369-380
• 50 Spranger J, Kroke A, Möhlig M. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003; 52: 812-817
• 51 Ellingsgaard H, Ehses JA, Hammar EB. et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 2008; 105: 13163-13168
• 52 Ellingsgaard H, Hauselmann I, Schuler B. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. 2011: 1481-1489
• 53 Millar P, Pathak N, Parthsarathy V. et al. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol 2017; 3: 255-267
• 54 Forst T, Falk A, Andersen G. et al. Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: an exploratory mechanistic study. Diabetes Obes Metab 2017; 19: 489-495
• 55 Saponaro C, Gmyr V, Thévenet J. et al. The GLP1R agonist liraglutide reduces hyperglucagonemia induced by the SGLT2 inhibitor dapagliflozin via somatostatin release. Cell Rep 2019; 28: 1447-1454.e4